Ceclor Articles
Diapharm organizes GMP inspection at Ranbaxy
13 May 2009
Ranbaxy debuts chewable cephalosporin tab
28 June 2004
Elan Corp set to acquire Dura Pharmaceuticals in $1.8 billion deal
11 September 2000
Ranbaxy forecasting strong growth in 2000
22 May 2000
Ranbaxy Sees Profits Take A 8.9% Tumble
9 November 1998
Lupin Set To Make Acquisition In USA
3 June 1998
SkyePharma Benefits From Lilly Trial Advance
15 May 1998
US Quarterly Financial Results Round-Up
23 April 1998
Ranbaxy Profits Rise, Aims For Further US Growth
8 April 1998
Analysts Losing Faith In Dura Pharma
4 March 1998
Profits Rise 24% For First Fiscal Half Year At Ranbaxy
21 October 1997
India: "Price Control On 75 More Drugs"
7 October 1997
Greek Govt Adjusts Prices Of 6,009 Drugs
3 October 1997
US HHS OKs MedGuides, Despite Objections
27 January 1997
Ranbaxy Launches Generic Cefaclor In UK
20 January 1997
HMR JV In S Africa
23 December 1996
Roussel Uclaf Stops Bulk Generics To USA
18 November 1996
US Quarterly Results Show Improvements
4 November 1996
Lilly Signs $100 Million Antibiotic Deal With Dura
2 September 1996
Patent Expiries Set To Drive Generics Boom
22 July 1996
Tactical Diversity In The Evolving US Health Market
17 June 1996
Generics Impact On Eli Lilly But Prozac Strong
22 April 1996
Effects of Genomics On Antibacterial R&D
20 November 1995
US 3rd Qrt Results: Strong Gains For Pfizer, Lilly
23 October 1995
Results To June 30 See Losses For Smaller US Firms
21 August 1995
Lilly/Zenith cefaclor case
14 August 1995
Solid 2nd Qtr Earnings Growth For US Drugmakers
17 July 1995
Weaker US Dollar And Volume Growth Lift 1st Qtr
24 April 1995
January Rx Trends In The USA
13 March 1995
Eli Lilly Opens Manufacturing Plant
6 March 1995
...And Israel's Teva Recommended
2 January 1995
Lilly Expands Argentine Presence
2 January 1995
Shionogi Posts Good Interim Sales
5 December 1994
Canada: Province's "Secret Pact With Drug Firms"
24 October 1994
Generics To Lead US Managed Care "Soon"
17 October 1994
Mylan/Lilly Agreement
17 October 1994
DDT's New Global Pharma Market Review 1994
10 October 1994
Benefits From PBM/MPC Acquisitions Assessed
15 August 1994
US FDA APPROVES NEW GENERICS
16 May 1994
LILLY TO MARKET GENERIC TAGAMET
25 April 1994
RECALL HITS 1st-QTR NET PROFITS AT LILLY
25 April 1994
US PRODUCT NEWS IN BRIEF
18 April 1994
LILLY RECALLS ANTIBIOTICS
11 April 1994
NEW YORK STOCK COMMENT
4 April 1994
RESTRUCTURING CHARGES DEPRESS LILLY AND E KODAK
14 February 1994
JAPANESE FIRST-HALF RESULTS AND FORECASTS
6 December 1993
WORLD MARKET FOR ANTI-INFECTIVES
15 November 1993
BIAXIN EFFECTIVE FOR OTITIS MEDIA
25 October 1993
ELI LILLY CHIEF IN RESIGNATION ROW
5 July 1993
BOOM FORECAST FOR US GENERICS HOUSES
5 July 1993
ROCHE LAUNCHES TWO PRODUCTS IN UK
12 April 1993
XENOVA IN CLINIC WITHIN 12 TO 18 MONTHS?
8 March 1993
US 4th QTR SHOWS NOT ALL COMPANIES STRONG
15 February 1993
DISTACLOR MR IN UK
25 January 1993
GLOBAL DRUG MARKET: 30 YEARS OF GROWTH
4 January 1993
JOB CUTS AT BRISTOL-MYERS SQUIBB
9 November 1992
US RESULTS 3RD QTR
2 November 1992
Tokyo: Stock Comment
6 July 1992
LILLY SUES OVER CECLOR IN JAPAN
6 July 1992
RESISTANCE ENSURES AUGMENTIN'S FUTURE
15 June 1992
US PRESCRIPTION PRICES UP 8.1%IN 1991
23 March 1992
FDA MOVE UPGRADES BIOCRAFT EARNINGS
9 March 1992
US GENERIC DRUG MARKET TO 1995
17 February 1992
BIOCRAFT SETS SIGHTS ON GENERIC CECLOR
17 February 1992
NEW CHEMICAL ENTITIES UPDATE FOR 1991
10 February 1992
DECEMBER US APPROS REVIEWED
20 January 1992
Showing 1-69 of 69 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
